Page last updated: 2024-12-07

l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107823
SCHEMBL ID194686
MeSH IDM0090501

Synonyms (15)

Synonym
rx-77368
rx 77368
l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide
l-prolinamide, 5-oxo-l-prolyl-l-histidyl-3,3-dimethyl-
76820-40-1
pyr-his-dmp-nh2
rx77368
pyaiku1m4k ,
5-oxo-l-prolyl-l-histidyl-3,3-dimethyl-l-prolinamide
unii-pyaiku1m4k
SCHEMBL194686
l-pyroglutamyl-l-histidyl-l-3,3-dimethylprolinamide
pglu-his-(3,3'-dimethyl)-pro-nh2
DTXSID10998141
5-hydroxy-n-[1-{2-[hydroxy(imino)methyl]-3,3-dimethylpyrrolidin-1-yl}-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-3,4-dihydro-2h-pyrrole-2-carboximidic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" It is concluded that the increased potency in neuropharmacological tests results from enhanced bioavailability to CNS sites and that a similar rationale can be used to explain the CNS selectively claimed in the literature for other analogues of TRH."( Thyrotropin-releasing hormone (TRH) analogues show enhanced CNS selectivity because of increased biological stability.
Brewster, D; Dettmar, PW; Havler, ME; Lynn, AG; Metcalf, G, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies revealed that the gastric acid secretion induced by submaximal but not high doses of RX 77368 was elevated significantly by p-CPA pretreatment."( Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants.
Garrick, T; Stephens, RL; Taché, Y; Weiner, H, 1989
)
0.28
" In rats the compound caused release of prolactin but the dose-response relationship was bi-phasic, so that large doses caused only a diminished response."( The ability of RX 77368 - a stabilised analogue of TRH - to provoke the secretion of prolactin and TSH in vivo.
Clifford, JM; Dettmar, PW; Lynn, AG; Metcalf, G, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (132)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (34.09)18.7374
1990's63 (47.73)18.2507
2000's20 (15.15)29.6817
2010's4 (3.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.21 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (5.07%)5.53%
Reviews1 (0.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other130 (94.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]